{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:45:32Z","timestamp":1791477932350,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Project of Science and Technology Program of Jiangxi Province Chinese Medicine for 2023","award":["2023B0202"],"award-info":[{"award-number":["2023B0202"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460498"],"award-info":[{"award-number":["82460498"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ganzhou Key Laboratory of Thyroid Tumors","award":["20220101-24"],"award-info":[{"award-number":["20220101-24"]}]},{"name":"Ganzhou Key Laboratory of Thyroid Tumors","award":["20220101-24"],"award-info":[{"award-number":["20220101-24"]}]},{"name":"Ganzhou Key Laboratory of Thyroid Tumors","award":["20220101-24"],"award-info":[{"award-number":["20220101-24"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14231-8","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:23:27Z","timestamp":1747207407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comprehensive network pharmacology and experimentation to unveil the therapeutic efficacy and mechanisms of gypenoside LI in anaplastic thyroid cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Meiyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqiao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanbing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangtai","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"5","key":"14231_CR1","first-page":"425","volume":"331","author":"L Boucai","year":"2024","unstructured":"Boucai L, Zafereo M, Cabanillas ME. Thyroid Cancer: Review[J] JAMA. 2024;331(5):425\u201335.","journal-title":"Thyroid Cancer: Review[J] JAMA"},{"issue":"3","key":"14231_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"6","key":"14231_CR3","first-page":"685","volume":"50","author":"C Qian","year":"2021","unstructured":"Qian C, Jiang L, Xu S. Advances in targeted therapy for anaplastic thyroid carcinoma[J]. Zhejiang Da Xue Xue Bao Yi Xue Ban = J Zhejiang Univ Med Sci. 2021;50(6):685\u201393.","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban = J Zhejiang Univ Med Sci"},{"key":"14231_CR4","doi-asserted-by":"publisher","first-page":"e942619","DOI":"10.12659\/MSM.942619","volume":"30","author":"A Aras","year":"2024","unstructured":"Aras A, Karayil AR. Optimal surgical approaches for thyroid cancer: A comparative analysis of efficacy and Complications[J]. Med Sci Monitor: Int Med J Experimental Clin Res. 2024;30:e942619.","journal-title":"Med Sci Monitor: Int Med J Experimental Clin Res"},{"issue":"3","key":"14231_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid Cancer[J]. Thyroid: Official J Am Thyroid Association. 2021;31(3):337\u201386.","journal-title":"Thyroid: Official J Am Thyroid Association"},{"key":"14231_CR6","doi-asserted-by":"publisher","first-page":"108836","DOI":"10.1016\/j.surg.2024.08.046","volume":"177","author":"K Dickerson","year":"2025","unstructured":"Dickerson K, Milas M, Metzger R. Neoadjuvant systemic therapy for inoperable differentiated thyroid cancers: impact on tumor resectability[J]. Surgery. 2025;177:108836.","journal-title":"Surgery"},{"key":"14231_CR7","doi-asserted-by":"crossref","unstructured":"Rao SN, Smallridge RC. Anaplastic thyroid cancer: An update[J]. Best Practice & Research. Clinical Endocrinology & Metabolism, 2023, 37(1): 101678.","DOI":"10.1016\/j.beem.2022.101678"},{"key":"14231_CR8","doi-asserted-by":"publisher","first-page":"113574","DOI":"10.1016\/j.jep.2020.113574","volume":"268","author":"NH Nguyen","year":"2021","unstructured":"Nguyen NH, Ha TKQ, Yang JL. Triterpenoids from the genus gynostemma: chemistry and Pharmacological activities[J]. J Ethnopharmacol. 2021;268:113574.","journal-title":"J Ethnopharmacol"},{"key":"14231_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13020-016-0114-9","volume":"11","author":"Y Li","year":"2016","unstructured":"Li Y, Lin W, Huang J. Anti-cancer effects of gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan)[J]. Chin Med. 2016;11:43.","journal-title":"Chin Med"},{"key":"14231_CR10","doi-asserted-by":"publisher","first-page":"113744","DOI":"10.1016\/j.phytochem.2023.113744","volume":"213","author":"HZ Liang","year":"2023","unstructured":"Liang HZ, Lu PX, Chu LL. Dammarane-type saponins from gynostemma pentaphyllum and their anti-aging activities via up-regulating mitochondria related proteins[J]. Phytochemistry. 2023;213:113744.","journal-title":"Phytochemistry"},{"key":"14231_CR11","doi-asserted-by":"publisher","first-page":"885039","DOI":"10.3389\/fendo.2022.885039","volume":"13","author":"SR Yue","year":"2022","unstructured":"Yue SR, Tan YY, Zhang L. Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2\/NLRP3 pathway[J]. Front Endocrinol. 2022;13:885039.","journal-title":"Front Endocrinol"},{"key":"14231_CR12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ijbiomac.2019.12.213","volume":"145","author":"Z Wang","year":"2020","unstructured":"Wang Z, Wang Z, Huang W. Antioxidant and anti-inflammatory activities of an anti-diabetic polysaccharide extracted from gynostemma pentaphyllum herb[J]. Int J Biol Macromol. 2020;145:484\u201391.","journal-title":"Int J Biol Macromol"},{"key":"14231_CR13","doi-asserted-by":"publisher","first-page":"107539","DOI":"10.1016\/j.bioorg.2024.107539","volume":"150","author":"MY Xiao","year":"2024","unstructured":"Xiao MY, Pei WJ, Li S. Gypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response[J]. Bioorg Chem. 2024;150:107539.","journal-title":"Bioorg Chem"},{"key":"14231_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jep.2018.03.012","volume":"219","author":"SF Xing","year":"2018","unstructured":"Xing SF, Liu LH, Zu ML. The inhibitory effect of gypenoside stereoisomers, gypenoside L and gypenoside LI, isolated from gynostemma pentaphyllum on the growth of human lung cancer A549 cells[J]. J Ethnopharmacol. 2018;219:161\u201372.","journal-title":"J Ethnopharmacol"},{"key":"14231_CR15","doi-asserted-by":"publisher","first-page":"820639","DOI":"10.3389\/fphar.2022.820639","volume":"13","author":"H Liu","year":"2022","unstructured":"Liu H, Li X, Xie J. Gypenoside L and gypenoside LI inhibit proliferation in renal cell carcinoma via regulation of the MAPK and arachidonic acid metabolism Pathways[J]. Front Pharmacol. 2022;13:820639.","journal-title":"Front Pharmacol"},{"key":"14231_CR16","doi-asserted-by":"publisher","first-page":"114017","DOI":"10.1016\/j.jep.2021.114017","volume":"273","author":"ML Zu","year":"2021","unstructured":"Zu ML, Duan Y, Xie JB. Gypenoside LI arrests the cell cycle of breast cancer in G0\/G1 phase by down-regulating E2F1[J]. J Ethnopharmacol. 2021;273:114017.","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"14231_CR17","doi-asserted-by":"publisher","first-page":"e22460","DOI":"10.1002\/jbt.22460","volume":"34","author":"ML Zu","year":"2020","unstructured":"Zu ML, Piao XL, Gao JM. Monomer gypenoside LI from gynostemma pentaphyllum inhibits cell proliferation and upregulates expression of miR-128-3p in melanoma cells[J]. J Biochem Mol Toxicol. 2020;34(5):e22460.","journal-title":"J Biochem Mol Toxicol"},{"issue":"1","key":"14231_CR18","doi-asserted-by":"publisher","first-page":"bbad518","DOI":"10.1093\/bib\/bbad518","volume":"25","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang D, Zhou W. Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine[J]. Brief Bioinform. 2023;25(1):bbad518.","journal-title":"Brief Bioinform"},{"issue":"5","key":"14231_CR19","doi-asserted-by":"publisher","first-page":"103979","DOI":"10.1016\/j.drudis.2024.103979","volume":"29","author":"JX Liu","year":"2024","unstructured":"Liu JX, Zhang X, Huang YQ. Multi-level bioinformatics resources support drug target discovery of protein-protein interactions[J]. Drug Discovery Today. 2024;29(5):103979.","journal-title":"Drug Discovery Today"},{"key":"14231_CR20","doi-asserted-by":"publisher","first-page":"116306","DOI":"10.1016\/j.jep.2023.116306","volume":"309","author":"L Zhao","year":"2023","unstructured":"Zhao L, Zhang H, Li N. Network Pharmacology, a promising approach to reveal the Pharmacology mechanism of Chinese medicine formula[J]. J Ethnopharmacol. 2023;309:116306.","journal-title":"J Ethnopharmacol"},{"issue":"13","key":"14231_CR21","doi-asserted-by":"publisher","first-page":"11166","DOI":"10.1021\/acsomega.1c07335","volume":"7","author":"K Wang","year":"2022","unstructured":"Wang K, Qian R, Li H. Interpreting the Pharmacological mechanisms of Sho-saiko-to on thyroid carcinoma through combining network Pharmacology and experimental Evaluation[J]. ACS Omega. 2022;7(13):11166\u201376.","journal-title":"ACS Omega"},{"issue":"1","key":"14231_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s12859-017-1871-x","volume":"18","author":"Y Li","year":"2017","unstructured":"Li Y, Ilie L. SPRINT: ultrafast protein-protein interaction prediction of the entire human interactome[J]. BMC Bioinformatics. 2017;18(1):485.","journal-title":"BMC Bioinformatics"},{"issue":"3","key":"14231_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41568-023-00656-5","volume":"24","author":"E Cambria","year":"2024","unstructured":"Cambria E, Coughlin MF, Floryan MA. Linking cell mechanical memory and cancer metastasis[J]. Nat Rev Cancer. 2024;24(3):216\u201328.","journal-title":"Nat Rev Cancer"},{"key":"14231_CR24","doi-asserted-by":"crossref","unstructured":"Chastney MR, Kaivola J, Lepp\u00e4nen VM. et.al. The role and regulation of integrins in cell migration and invasion[J]. Nat Rev Mol Cell Biol, 2024.","DOI":"10.1038\/s41580-024-00777-1"},{"issue":"1","key":"14231_CR25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12935-022-02801-w","volume":"22","author":"P Bouchalova","year":"2022","unstructured":"Bouchalova P, Bouchal P. Current methods for studying metastatic potential of tumor cells[J]. Cancer Cell Int. 2022;22(1):394.","journal-title":"Cancer Cell Int"},{"key":"14231_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","volume":"94","author":"R Roskoski","year":"2015","unstructured":"Roskoski R. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors[J]. Pharmacol Res. 2015;94:9\u201325.","journal-title":"Pharmacol Res"},{"issue":"8","key":"14231_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41419-023-05987-7","volume":"14","author":"R Xu","year":"2023","unstructured":"Xu R, Song J, Ruze R. SQLE promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src\/PI3K\/Akt signaling pathway[J]. Cell Death Dis. 2023;14(8):497.","journal-title":"Cell Death Dis"},{"issue":"1","key":"14231_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12964-021-00750-x","volume":"19","author":"MA Ortiz","year":"2021","unstructured":"Ortiz MA, Mikhailova T, LI X. Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition[J]. Cell Communication Signaling: CCS. 2021;19(1):67.","journal-title":"Cell Communication Signaling: CCS"},{"issue":"3","key":"14231_CR29","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7150\/ijbs.91786","volume":"20","author":"CW Lin","year":"2024","unstructured":"Lin CW, Yang WE, Su CW. IGF2BP2 promotes cell invasion and epithelial-mesenchymal transition through Src-mediated upregulation of EREG in oral cancer[J]. Int J Biol Sci. 2024;20(3):818\u201330.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"14231_CR30","first-page":"235","volume":"187","author":"K Newton","year":"2024","unstructured":"Newton K, Strasser A, Kayagaki N. Et Al Cell death[J] Cell. 2024;187(2):235\u201356.","journal-title":"Et Al Cell death[J] Cell"},{"issue":"9","key":"14231_CR31","first-page":"1188","volume":"43","author":"JK CHUNG","year":"2002","unstructured":"CHUNG JK. Sodium iodide symporter: its role in nuclear medicine[J]. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2002;43(9):1188\u2013200.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"issue":"1","key":"14231_CR32","doi-asserted-by":"publisher","first-page":"21440","DOI":"10.1038\/s41598-020-78574-x","volume":"10","author":"H Rakhsh-Khorshid","year":"2020","unstructured":"Rakhsh-Khorshid H, Samimi H, Torabi S. Network analysis reveals essential proteins that regulate sodium-iodide symporter expression in anaplastic thyroid carcinoma[J]. Sci Rep. 2020;10(1):21440.","journal-title":"Sci Rep"},{"issue":"2","key":"14231_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","volume":"43","author":"C Nogales","year":"2022","unstructured":"Nogales C, Mamdouh ZM, List M. Network pharmacology: curing causal mechanisms instead of treating symptoms[J]. Trends Pharmacol Sci. 2022;43(2):136\u201350.","journal-title":"Trends Pharmacol Sci"},{"issue":"17","key":"14231_CR34","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1242\/dev.137075","volume":"143","author":"JSL Yu","year":"2016","unstructured":"Yu JSL, Cui W. Proliferation, survival and metabolism: the role of PI3K\/AKT\/mTOR signalling in pluripotency and cell fate determination[J]. Development. 2016;143(17):3050\u201360.","journal-title":"Development"},{"issue":"1","key":"14231_CR35","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG. Targeting PI3K\/Akt signal transduction for cancer therapy[J]. Signal Transduct Target Therapy. 2021;6(1):425.","journal-title":"Signal Transduct Target Therapy"},{"issue":"10","key":"14231_CR36","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3390\/cells9102245","volume":"9","author":"M Izdebska","year":"2020","unstructured":"Izdebska M, Zieli\u0144ska W, HA\u0141AS-WI\u015aNIEWSKA, M. Involvement of actin and actin-Binding proteins in Carcinogenesis[J]. Cells. 2020;9(10):2245.","journal-title":"Cells"},{"issue":"1","key":"14231_CR37","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41467-024-46868-7","volume":"15","author":"R Kumari","year":"2024","unstructured":"Kumari R, Ven K, Chastney M. Focal adhesions contain three specialized actin nanoscale layers[J]. Nat Commun. 2024;15(1):2547.","journal-title":"Nat Commun"},{"issue":"1","key":"14231_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1146\/annurev-biochem-030222-120000","volume":"93","author":"JM Paggi","year":"2024","unstructured":"Paggi JM, Pandit A, Dror RO. The Art and science of molecular Docking[J]. Annu Rev Biochem. 2024;93(1):389\u2013410.","journal-title":"Annu Rev Biochem"},{"issue":"8","key":"14231_CR39","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.3390\/ijms22084196","volume":"22","author":"L Paladino","year":"2021","unstructured":"Paladino L, Vitale AM, Santonocito R. Molecular chaperones and thyroid Cancer[J]. Int J Mol Sci. 2021;22(8):4196.","journal-title":"Int J Mol Sci"},{"key":"14231_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-3-030-47189-7_4","volume":"1270","author":"A Caner","year":"2021","unstructured":"Caner A, Asik E, Ozpolat B. SRC signaling in Cancer and tumor Microenvironment[J]. Adv Exp Med Biol. 2021;1270:57\u201371.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"14231_CR41","doi-asserted-by":"publisher","first-page":"e202201159","DOI":"10.1083\/jcb.202201159","volume":"221","author":"E Eskandari","year":"2022","unstructured":"Eskandari E, Eaves CJ. Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis[J]. J Cell Biol. 2022;221(6):e202201159.","journal-title":"J Cell Biol"},{"issue":"7","key":"14231_CR42","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41417-024-00765-9","volume":"31","author":"J Gao","year":"2024","unstructured":"Gao J, Xiong A, Liu J. PANoptosis: bridging apoptosis, pyroptosis, and necroptosis in cancer progression and treatment[J]. Cancer Gene Ther. 2024;31(7):970\u201383.","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"14231_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"JA Fresno Vara","year":"2004","unstructured":"Fresno Vara JA, Casado E, De Castro J. PI3K\/Akt signalling pathway and cancer[J]. Cancer Treat Rev. 2004;30(2):193\u2013204.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"14231_CR44","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","volume":"79","author":"M Song","year":"2019","unstructured":"Song M, Bode AM, Dong Z. AKT as a therapeutic target for Cancer[J]. Cancer Res. 2019;79(6):1019\u201331.","journal-title":"Cancer Res"},{"issue":"7","key":"14231_CR45","doi-asserted-by":"publisher","first-page":"e13608","DOI":"10.1111\/cpr.13608","volume":"57","author":"MR Khezri","year":"2024","unstructured":"Khezri MR, Hsueh HY, Mohammadipanah S. The interplay between the PI3K\/AKT pathway and circadian clock in physiologic and cancer-related pathologic conditions[J]. Cell Prolif. 2024;57(7):e13608.","journal-title":"Cell Prolif"},{"issue":"1","key":"14231_CR46","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12935-023-02967-x","volume":"23","author":"PF Karmokar","year":"2023","unstructured":"Karmokar PF, Moniri NH. Free-fatty acid receptor-1 (FFA1\/GPR40) promotes papillary RCC proliferation and tumor growth via Src\/PI3K\/AKT\/NF-\u03baB but suppresses migration by Inhibition of EGFR, ERK1\/2, STAT3 and EMT[J]. Cancer Cell Int. 2023;23(1):126.","journal-title":"Cancer Cell Int"},{"key":"14231_CR47","doi-asserted-by":"crossref","unstructured":"Sim\u00f3n L, Torres K, Contreras P. et.al. Inhibition of Glycolysis and Src\/Akt signaling reduces Caveolin-1-enhanced metastasis[J]. Volume 176. Biomedicine & Pharmacotherapy\u2009=\u2009Biomedecine & Pharmacotherapie; 2024. p. 116841.","DOI":"10.1016\/j.biopha.2024.116841"},{"key":"14231_CR48","doi-asserted-by":"publisher","first-page":"156441","DOI":"10.1016\/j.phymed.2025.156441","volume":"139","author":"Y Li","year":"2025","unstructured":"Li Y, Dong M, Qin H. Mulberrin suppresses gastric cancer progression and enhances chemosensitivity to oxaliplatin through HSP90AA1\/PI3K\/AKT axis[J]. Phytomedicine: Int J Phytotherapy Phytopharmacology. 2025;139:156441.","journal-title":"Phytomedicine: Int J Phytotherapy Phytopharmacology"},{"issue":"1","key":"14231_CR49","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13046-018-0880-6","volume":"37","author":"X Xiao","year":"2018","unstructured":"Xiao X, Wang W, Li Y. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma[J]. J Experimental Clin cancer Research: CR. 2018;37(1):201.","journal-title":"J Experimental Clin cancer Research: CR"},{"issue":"4","key":"14231_CR50","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1089\/thy.2018.0626","volume":"30","author":"JM Oh","year":"2020","unstructured":"Oh JM, Baek SH, Gangadaran P. A novel tyrosine kinase inhibitor can augment radioactive iodine uptake through endogenous sodium\/iodide symporter expression in anaplastic thyroid cancer[J]. Thyroid: Official J Am Thyroid Association. 2020;30(4):501\u201318.","journal-title":"Thyroid: Official J Am Thyroid Association"},{"issue":"1","key":"14231_CR51","doi-asserted-by":"publisher","first-page":"16844","DOI":"10.1038\/s41598-023-43486-z","volume":"13","author":"ACL Mortensen","year":"2023","unstructured":"Mortensen ACL, Berglund H, Hariri M. Combination therapy of tyrosine kinase inhibitor Sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer[J]. Sci Rep. 2023;13(1):16844.","journal-title":"Sci Rep"},{"issue":"3","key":"14231_CR52","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3892\/or.2015.3735","volume":"33","author":"S Hashida","year":"2015","unstructured":"Hashida S, Yamamoto H, Shien K. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors[J]. Oncol Rep. 2015;33(3):1499\u2013504.","journal-title":"Oncol Rep"},{"issue":"15","key":"14231_CR53","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1200\/JCO.2014.59.7328","volume":"33","author":"ML Johnson","year":"2015","unstructured":"Johnson ML, Yu HA, Hart EM. Phase I\/II study of HSP90 inhibitor AUY922 and erlotinib for EGFR-Mutant lung Cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors[J]. J Clin Oncology: Official J Am Soc Clin Oncol. 2015;33(15):1666\u201373.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14231-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14231-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14231-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:06:36Z","timestamp":1747209996000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14231-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14231"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14231-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were evaluated and approved by the Animal Care and Use Committee of Gannan Medical University (No. LLSC-2024077).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"870"}}